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Abstract
Background: In 2003, a major epidemic of human immunodeficiency virus emerged among injection drug users in
Taiwan. In response to the twin epidemics of HIV and intravenous drug addiction, the government implemented
comprehensive harm reduction programs beginning in 2005. Collected data from relevant agencies were used to
explore the impact of the harm reduction programs on HIV and illicit drug use.
Methods: This study divided 2002–2015 into three intervention phases and used the surveillance data and statistics
on the HIV epidemic, drug abuse, and the intervention from relevant agencies to explore the correlations between
different variables in different intervention periods and the combination effects of interventions on the HIV
epidemic.
Results: In the pre-intervention phase, the growth of the HIV epidemic followed the rapidly increasing number of
heroin users, reaching a peak in 2005. After the initiation of harm reduction programs, the HIV epidemic ceased
growing, even rapidly declining with the expansion of needle and syringe exchange programs and opioid
substitution therapy; however, the number of heroin users remained high. When the implementation of the needle
and syringe exchange programs and the opioid substitution therapy program reached the plateau level in the
consolidation phase, the number of heroin users also decreased rapidly. The combination effects of the harm
reduction programs in this period also pushed levels of HIV infection below those before this outbreak.
Conclusions: The HIV epidemic among injection drug users incorporates the dual problems of drug addiction and
needle-sharing behaviors, so the use of a single intervention will not resolve all of the problems. Facing a severe
HIV epidemic among injection drug users, quickly scaling up and promoting comprehensive harm reduction
programs is a good strategy that can be used to simultaneously reverse the HIV epidemic and to resolve the illicit
drug use problems.
More research is needed to find out the reasons behind why there were cases that declined opioid substitution
therapy, so that efforts can be undertaken to avoid the epidemic rebounding.
Keywords: Human immunodeficiency virus, Comprehensive harm reduction programs, Injection drug users, Needle
and syringe exchange programs, Opioid substitution therapy, Combination intervention approaches, Forced
withdrawal, Relapse
Background
Globally, injection drug users (IDUs) have been identi-
fied in at least 158 countries and territories [1]. IDUs are
susceptible to blood-borne infectious diseases, such as
human immunodeficiency virus (HIV) infection [2–4].
In 2013, the number of IDUs worldwide was estimated
to be around 12.19 million (range 8.48–21.46 million),
and among these, about 1.65 million (range 0.92–4.42
million) were estimated to be infected with HIV [5].
Comprehensive harm reduction programs are remark-
ably effective in controlling HIV among IDUs and are
also recommended by the Joint United Nations Program
on HIV/AIDS (UNAIDS), the United Nations Office on
Drugs and Crime (UNODC), and the World Health
Organization (WHO) [6]. Cost-effective interventions,
including needle and syringe exchange programs (NSPs),
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opioid substitution therapy (OST), and expanded access
to HIV treatment and care, are supported on public
health and human rights grounds [7, 8]; however, at the
global level, harm reduction responses related to unsafe
injection remain poor [5]. In 2014, 91 countries included
harm reduction programs in their national policies,
NSPs were available in 90 countries, and OST was avail-
able in 80 countries. Moreover, in many countries, the
availability of harm reduction services remain at levels
below minimum levels recommended by international
guidance [5, 9].
It is crucial for regions with rapidly growing epidemics
to optimize the effectiveness and coverage of interven-
tions. Each intervention will achieve only modest reduc-
tions in HIV transmission alone, and the elimination of
HIV transmission necessitates high coverage and com-
bined approaches [10–12]. In 2003, a major HIV epi-
demic among IDUs emerged in Taiwan. Following the
rapid increase in the heroin users, the number of IDUs
newly infected with HIV also increased from 80,620
(9.3 %, 40.8 % of all newly reported HIV cases) in 2003
and 2004, respectively, to a peak level of 2420 (71.6 % of
all newly reported HIV cases) in 2005.
In response to this HIV epidemic, the government se-
cured a political commitment to implement comprehen-
sive harm reduction programs in 2005. We collected
nationwide data from relevant agencies to explore the
impact of harm reduction programs on HIV and illicit
drug use in Taiwan.
Methods
The materials used in this research included data from
the following agencies: (a) 2002–2015: the annual num-
ber of newly reported HIV infection cases and cases
among IDUs collected from the national HIV/AIDS
reporting system of the Taiwan Centers for Disease Con-
trol (TCDC) [13]; (b) 2002–2015: the number of “urine
specimens that have a morphine reaction” and the num-
ber of heroin users reported by hospitals collected from
the Food and Drug Administration [14]; (c) 2003–2014:
the percentage of drug delivery methods among drug ad-
dicts reported from hospitals collected from the Annual
anti-drug report [15]; (d) 2005–2015: the number of
NSP sites and the total annual number of needles-
syringes distributed collected from the data of harm re-
duction programs in the TCDC [16]; (e) 2006–2012: the
number of OST clinics, the number of cases in OST, and
the total annual person-days collected from TCDC [17];
and (e) additional data from 2013 to 2015 collected from
the Ministry of Health and Welfare [18].
The frequency distribution of the variables in this
study are described in Table 1.


































2002 23,385 6233 29,618 767 18 2.3
2003 27,741 7353 35,094 860 80 9.3
2004 32,283 11,479 43,762 1521 620 40.8
2005 39,123 11,466 50,589 3380 2420 71.6 76 12,568
2006 34,775 11,219 45,994 2918 1839 63.0 729 438,081 21 641 66,287
2007 36,625 17,614 54,235 1930 742 38.4 1194 3,634,414 71 5585 1,225,027
2008 36,362 20,096 56,458 1742 386 22.2 1521 4,066,114 90 12,598 3,071,639
2009 24,516 17,657 42,173 1644 178 10.8 1272 3,097,348 97 11,519 2,904,644
2010 21,505 17,176 38,674 1795 116 6.5 1331 3,586,071 100 11,750 2,964,509
2011 18,501 14,020 32,521 1968 111 5.6 1302 3,497,991 102 11,991 3,107,275
2012 18,668 12,429 31,097 2222 86 3.9 1364 3,557,660 102 11,127 3,113,635
2013 14,541 13,458 27,999 2243 48 2.1 1353 3,259,129 117 10,651 3,567,611
2014 12,666 11,298 23,964 2235 52 2.3 1278 3,674,650 133 9231 2,553,545
2015 14,260 11,697 25,957 2327 82 3.5 1252 3,860,518 162 8789 2,570,744
*Heroin in the body will be metabolized into morphine. Specimens came from the drug abuse urine-testing laboratory accredited by the Ministry of Health and
welfare, the Food and Drug Administration, county and city health bureau, Ministry of Justice Investigation Bureau, National Police Agency Criminal Investigation
Bureau, and the Military Police Command
¥These cases do not include OST cases
#NSP sites include pharmacy-based NSP sites and vending machines
¶OST clinics include the clinics of psychiatric hospitals and the clinics of local health stations
§Persons whose attendance rate in OST program was over 70 %
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In order to explore the correlation between different
variables in different periods, the combination effects of
the interventions on the HIV infection were also evalu-
ated. For the figures, time was plotted on the horizontal
axis and the frequency distribution of the variables was
plotted on the vertical axis. We divided the whole period
into three different phases of intervention. The pre-
intervention phase is the time before August 2005. In
November 2008, the OST program reached the plateau
level, so the time after August 2005 to November 2008
was set as the expanding phase. The period of time after
November 2008 was set as the consolidation phase.
To compare the correlation of the two continuous var-
iables, we used the Person correlation method to calcu-
late the correlation coefficient (r). When calculating the
combined effects of NSPs and OST, we used the
multiple-regression method. We used SPSS statistical
software to analyze the data, and a p value ≤0.05 was
considered statistically significant.
Results
The temporal trend and correlation of illicit drug use and
the HIV epidemic among IDUs
In Taiwan, there is no long-term epidemiological studies
on the prevalence of opiate use in the general popula-
tion. Therefore, some data from the Food and Drug Ad-
ministration was used as indicators to represent the data
of IDUs. The first data is the number of “urine speci-
mens that have a morphine reaction.” These specimens
originated from many different agencies and institutes
whose sources are more comprehensive (Table 1). We
used these numbers as low estimate numbers of IDUs,
and these numbers plus the numbers of heroin cases re-
ported by the hospitals were used as the estimate num-
bers of IDUs.
In 2003, a major HIV epidemic among IDUs emerged
in Taiwan. Following the rapidly increasing number of
heroin users, the number of IDUs newly infected with
HIV also increased from 80 (9.3 % of all new HIV cases)
to its highest point 2420 (71.6 % of all new HIV cases) in
2005. After the initiation of harm reduction programs, it
stopped growing and declined quickly. Between 2005
and 2013, the number of newly infected HIV cases
among IDUs decreased from 2420 (71.6 % of all new
HIV cases) to 48 (2.1 % of all new HIV cases); however,
it increased slightly to 82 (3.5 % of all new HIV cases)
in 2015.
During the early stages of intervention, the drug addic-
tion epidemic remained at a plateau level for a few years
and did not decline until 2008 (totaling 50,589, 45,994,
54,235, and 56,458 in 2005–2008, respectively). After the
implementation of the OST program reached a plateau
level in 2008, and the stages of the intervention passed
over into the consolidation stage, the drug addiction
epidemic also reversed, entering a rapid decline, from
42,173 in 2009 to 23,964 in 2014, even lower than
29,618 in 2002. However, it slightly increased to 25,957
in 2015.
Speaking generally, we found that illicit drug use had a
strong influence on HIV infection among IDUs, and the
trend of HIV infection among IDUs followed the trend
of both estimated numbers of illicit drug use (compared
with the estimates, r = 0.61, p < 0.05; and compared with
the low estimates, r = 0.72, p < 0.01, Fig. 1).
The correlation of NSP’s implementation and the trend of
HIV infection among IDUs
Following the implementation of pilot programs in four
administrative areas, NSPs were introduced in Novem-
ber 2005, and the first clean syringe dispensary was initi-
ated at the same time. At the end of year 2005, there
were 76 dispensing sites and 12,568 clean syringes had
been dispensed. After evaluating the effectiveness of the
pilot plan, the Ministry of Health initiated an expansion
of this program nationwide in July 2006, quickly setting
up clean needle exchange stations in 23 administrative
areas; by the end of 2006, the number of NSP sites had
reached 729, and the number of needles and syringes
distributed rose up to 438,081 items. NSP coverage
reached a plateau in 2007, peaking in 2008, when a total
number of 1521 distribution sites had been set up and a
total of 4,066,114 needles and syringes had been distrib-
uted. The NSP trend then remained on this plateau until
2015, with an average level of about 1300 distribution
sites set up per year and issuing about 3.5 million pieces
of clean needles and syringes each year. The trend of
HIV infection among IDUs stopped growing after the
harm reduction programs began and declined subse-
quent to NSP growth. There was a negative correlation
between the trends of HIV infection among IDUs and
NSP implementation (compared with the total annual
number of needles and syringes distributed, r = −0.94,
p < 0.01; and compared with the number of NSP sites,
r = −0.94, p < 0.01, Fig. 2).
In 2005–2008, when the NSP implementation grew
rapidly, the number of heroin addicts remained at a plat-
eau level. This seemed to show that NSPs solved the
problem of sharing behaviors, which quickly reduced
HIV infection rates. However, fundamentally, NSPs can-
not solve addiction problems, and many people continue
to use drugs.
The correlation of OST implementation and the trend of
heroin addiction epidemic
The OST program began in February 2006 with the first
heroin addict being admitted to the Taoyuan Psychiatric
Hospital to receive methadone maintenance treatment.
This later expanded to the whole country in August
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2006. At the end of 2006, 21 methadone clinics had been
established, with 641 individuals regularly taking medi-
cine from them; the total annual person-days reached
66,287. The implementation of the OST program
reached a plateau level in 2008 (90 clinics, 12,598 per-
sons regularly receiving medication, and the total annual
person-days was 3,071,639). OST coverage was main-
tained at a plateau level for years, until 2013 (with an
average level of about over 100 clinics set up, about
11,000 persons regularly taking the medicine, and about
3 million total annual person-days). Later, in the years
2014 and 2015, the coverage of the OST program was
slightly reduced; however, it was still maintained to a
considerable degree.
The number of heroin addicts increased rapidly from
2003 reaching the plateau in 2005. Although harm re-
duction programs began in August 2005, the OST pro-
gram began later than the NSP program and also
reached a plateau later than the NSP program. There-
fore, the drug addiction epidemic was maintained at a
plateau level and did not decline until 2008. Following
the implementation of the OST program reaching a plat-
eau level in 2008, the number of drug addicts also re-
versed, rapidly declining from 42,173 in 2009 to 23,964
in 2014. In 2015, following the coverage of the OST pro-
gram being slightly reduced, the number of heroin users
also increased to 25,957. There were negative correla-
tions between the implementation of the OST program
Fig. 1 The temporal trend and correlation of illicit drug use and HIV epidemic among IDUs. The relationships were positively correlated, r = 0.61,
p < 0.05, and r = 0.72, p < 0.01
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and the trends of the heroin addiction epidemic (nega-
tive correlation between the annual total person-days
with both of the two estimated numbers of heroin users,
r = −0.43, p = 0.11, and r = −0.60, p < 0.05, respectively
(Fig. 3)).
The correlation coefficient of the OST program and
the low estimates of IDUs (the number of urine speci-
mens with a morphine reaction could be referred to as
the number of heroin users not linked to medical care)
was r = −0.60, p < 0.05. After taking into account the
Fig. 3 The correlation of the OST program implementation and the trend of the heroin addiction epidemic. They were negatively correlated, r = −0.43,
p = 0.11 and r = −0.60, p < 0.05
Fig. 2 The correlation of NSP’s implementation and the trend of HIV epidemic among IDUs. The relationships were negative correlated, r = −0.94,
p < 0.01, and r = −0.94, p < 0.01
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number of heroin users that are linked to medical care,
the correlation coefficient decreased to r = −0.43, p =
0.11. Therefore, the implementation of OST program can
reduce the number of heroin addicts, especially those who
are not linked to medical services.
Combination effects of harm reduction interventions in
different intervention periods
The whole period of 2002–2015 was divided into three
different intervention phases. During the pre-intervention
phase, there were no harm reduction implementations ini-
tiated in this period, apart from educational projects. Illicit
drug use and the HIV infection cases among IDUs in-
creased very rapidly. The trend of HIV infection among
IDUs peaked in 2005, and after the initiation of harm
reduction programs, the trend of HIV infection among
IDUs stopped increasing.
During the expansion phase of the harm reduction
programs, the HIV epidemic rapidly declined with the
expansion of NSPs and the OST program. However, the
number of heroin users remaining at a plateau level did
not decrease at that time. Although the expansion of the
OST program occurred later than that of the NSPs, the
OST program still influenced the HIV epidemic. There
were negative correlation between the trends of HIV in-
fection among IDUs and OST implementation (compared
with the total annual person-days, r = −0.92, p < 0.01;
compared with the number of cases on OST program,
r = −0.89, p < 0.01; and compared with the number of
OST clinics, r = −0.86, p < 0.01).
When the implementation of the NSP and OST pro-
grams reached a plateau in the consolidation phase, the
OST program reached a high level of effectiveness, and
the number of heroin users decreased steeply. The com-
bination effects of harm reduction programs in this
period also dropped the number of HIV infection among
IDUs eventually to levels from before the beginning of
the epidemic.
When calculating the combined effects of NSPs and
OST, we used the multiple-regression method. Each
intervention variable of NSPs or OST program inde-
pendently influenced the HIV epidemic. When the com-
bined effects of NSPs and the OST program were taken
into account, the coefficient of determination (R2) value
of NSPs when controlled for OST (R2 = 0.746) and the
value of the OST program when controlled for NSPs
(R2 = 0.852) increased to R2 = 0.922; the explained vari-
ance of the dependent variable increased by 17.6 and
7.0 %, respectively (Fig. 4).
Suppose the estimate number in our study is an un-
biased estimate of IDUs, then we can use the estimate
number of IDUs to calculate the coverage level of NSPs
and the OST program. During the consolidation phase,
the average number of needles obtained by each person
in each year was 123 (range 92–149), and the average
percentage of OST participants among IDUs was 34.8 %
(range 27.3–39.5 %). When compared to other countries,
the coverage level was satisfactory.
The effects of harm reduction interventions on
needle-sharing behavior
From the annual anti-drug report, there were some data
from hospitals describing the proportion of different pat-
terns of drug use. Even though it did not distinguish opiates
with other drugs, the pattern of drug use by injection and
needle-sharing behavior was described in these reports. We
included it to present the effects of harm reduction inter-
ventions on needle-sharing behavior (Table 2).
From the data reported by hospitals in Fig. 5, we found
that the percentage of IDUs among drug user fluctuated
up and down during 2003 to 2014, but the trend of
needle-sharing behavior among IDUs declined gradually
following the initiation and expansion of the harm reduc-
tion programs. Needle-sharing behavior declined steeply
when the implementation of the harm reduction programs
reached the high level seen in 2008. The trend of sharing
behavior was also consistent with the trend of the HIV
epidemic. The implementation of NSPs and OST program
were negatively correlated with the trend of sharing be-
havior (compared with the annual total needles-syringes
distributed, r = −0.74, p < 0.01; and compared with the an-
nual total person-days, r = −0.90, p < 0.01).
Discussion
In this study, we found that:
(1)The illicit drugs, particularly heroin, have a strong
impact on the HIV epidemic among IDUs.
(2)The NSPs can contribute to the control of the HIV
epidemic. However, NSPs cannot solve the drug
addiction problem among IDUs.
(3)The implementation of OST programs can reduce
the number of heroin addicts, especially those who
are not linked to medical services.
(4)The popularity of the harm reduction service sites
improved the accessibility of services and involved
more of the target population to participate in the
programs.
(5)A combination approach of interventions can
increase the synergistic effects of the individual
programs on HIV epidemic.
(6)The implementation of NSPs and OST programs
can reduce the proportion of IDUs engaging in
needle-sharing behaviors.
Some other key factors for the success of harm reduc-
tion programs in Taiwan can also be analyzed as followed:
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(1) To confront the epidemics of illicit drug use and HIV
among IDUs, early alerts and rapid responses are crucial.
(2) The rapid expansion from a pilot plan limited to
four administrative areas to nationwide harm
reduction programs within a year quickly amplified
the coverage levels of the interventions.
(3) Through communication, a consensus was reached
among law enforcement agencies and public heath
sectors to support the implementation of the
programs and to create good cross-sectoral cooper-
ation at the level of both central and local
government.
(4) Consistent cooperation with international partners
and studying and learning fully from the successful
experience of other countries shortened the period
of trial and error.
Fig. 4 Combination effects of harm reduction interventions in different intervention periods. Each intervention variable of NSPs or OST program
independently influenced the HIV epidemic. When the combined effects of NSPs and the OST program were taking into account, the coefficient
of determination (R2) value of NSPs when controlled of OST (R2 = 0.746) and the value of OST program when controlled of NSPs (R2 = 0.852),
respectively, increased to R2 = 0.922
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(5) Through the engagement of stakeholders, critical
information, such as feedback from drug users and
peer volunteers of non-governmental organizations
(NGOs), can be used to amend harm reduction
programs and to tailor the programs to meet the
needs of the target population [19].
Even though the harm reduction programs were suc-
cessfully implemented in Taiwan, a new problem, IDUs
dropping out of the OST program has emerged. In
Taiwan, the OST program has only been implemented
in communities and not in the correctional system.
When people who are receiving methadone maintenance
treatment for opioid dependence become incarcerated,
methadone treatment is discontinued abruptly. Non-
governmental organization Taiwan AIDS Foundation
(TAF) regularly engages in health education in correc-
tional facilities. According to peer volunteers of TAF,
because OST is ended abruptly once a person is incar-
cerated, the withdrawal symptoms that can last 2–
3 weeks or more often cause the incarcerated to hesitate
to return to the treatment system. This discontinuation
situation, which has also been observed in other coun-
tries, can induce uncomfortable symptoms of withdrawal
and cause prisoners to be susceptible to relapse and
overdose on release [20, 21]. We found that the coverage
of OST is slightly reduced from 2013 to 2015 (even
though sites providing medication increased from 117 to
162, the number of regular cases in OST have declined
from 10,651 to 8789, and the total annual person-days
have also declined from 3,567,611 to 2,570,744). At the
same time, as the coverage of the OST program de-
clined, the number of heroin users fluctuated down and
up from 27,999 to 23,964 to 25,957, and the number of
newly reported HIV cases among IDUs also increased
from 48 to 82. This situation acts as an early warning
about challenges to the long-term success of the current
programs. More research is needed to find out the rea-
sons behind why there were cases that declined opioid
substitution therapy, so that efforts can be undertaken
to avoid the epidemic rebounding.
Our study has some limitations. Core intervention
components should include access to antiretroviral ther-
apy, but antiretroviral therapy has been available free of
cost in Taiwan since 1997 even in prisons, so data on
Fig. 5 The effects of harm reduction interventions on needle-sharing behavior. They were negatively correlated, r = −0.74, p < 0.01 and
r = −0.90, p < 0.01
Table 2 The percentage of the pattern of drug use by injection
and needle-sharing behavior among drug user reported by
hospital














2003 8283 63.2 15.3 24.2
2004 12,232 63.9 15.0 23.5
2005 12,258 56.3 11.6 20.6
2006 11,967 58.9 10.7 18.2
2007 18,776 65.3 10.1 18.3
2008 21,574 67.3 5.2 7.7
2009 19,125 69.7 7.2 10.3
2010 18,792 70.6 6.1 8.6
2011 17,076 68.6 3.4 5.0
2012 18,562 57.2 3.0 5.2
2013 19,535 58.8 2.6 4.4
2014 17,896 50.9 2.6 5.1
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the access to antiretroviral therapy was not included in
this study. Information, education, and communication
(IEC) are also very important; feedback from drug users
and peer volunteers of NGOs can be used to amend the
harm reduction programs and to tailor the programs to
meet the needs of the target population [19]. However,
most of the education programs either have been imple-
mented before the harm reduction programs or have
been integrated into OST or NSPs programs, and there
is a lack of quantitative data, so it was not regarded as a
separate factor in this study. Even so, with these limita-
tions, there has been a study using an individual-level
analysis of the amnesty cohort in Taiwan. They found
that attendance at methadone clinics was associated with
a significantly lower HIV incidence, and frequent users
of needle/syringe program services had lower HIV inci-
dence [22]. These findings also support our study.
Without cross-country comparisons, the inferences of
the research results must also be restricted. However,
country-level comparisons and modeling projection
studies in western countries have shown that the extent
of coverage of OST and NSPs is associated with the inci-
dence and prevalence of HIV among IDUs. The experi-
ences of scaled-up harm reduction responses in Malaysia
have provided an example of effective practices that can
be used in Asia. All these evidence-based studies support
our findings [23–25]. From a global point of view, the
level of harm reduction responses related to unsafe in-
jection remains poor, and program implementation
remains at levels below the international minimum
guidelines in many countries [5]. We have sufficient
knowledge on which actions are effective, but the prob-
lem is implementing these actions well and to the appro-
priate scale. In this study, nationwide data from various
surveillance systems that covered the different phases of
the interventions were collected, and the mechanism of
actions that could provide a complete picture of harm
reduction implementation in Taiwan was analyzed.
Taiwan’s experience can be used as a reference by coun-
tries suffering from HIV epidemics among IDUs, so that
they may more effectively assess and implement their
national intervention programs.
Conclusions
The implementation of these government-initiated compre-
hensive harm reduction programs has curtailed the HIV epi-
demic among IDUs in Taiwan. Our findings suggest that
countries suffering from HIV epidemics among IDUs should
offer comprehensive harm reduction programs and should
fully scale up such implementations for their population.
More research is needed to find out the reasons
behind why there were cases that declined opioid substi-
tution therapy, so that efforts can be undertaken to
avoid the epidemic rebounding.
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